We are live on ! Find out more
SNDX icon

Syndax Pharmaceuticals
SNDX

63 hedge funds and large institutions have $160M invested in Syndax Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 19 increasing their positions, 11 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 3

100% more capital invested

Capital invested by funds: $79.8M → $160M (+$80.1M)

73% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 11

11% more funds holding

Funds holding: 57 → 63 (+6)

2.73% more ownership

Funds ownership: 61.15% → 63.89% (+2.7%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
63
Holders Change
+6
Holders Change %
+10.53%
% of All Funds
1.57%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
15
Increased
19
Reduced
11
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BlackRock
BlackRock
New York
+$14.8M
2
HIM
Hillhouse Investment Management
Cayman Islands
+$2.55M
3
ACH
ArrowMark Colorado Holdings
Colorado
+$2.48M
4
AG
Artal Group
Luxembourg
+$2.08M
5
Millennium Management
Millennium Management
New York
+$2.05M

Top Sellers

1
O
OrbiMed
New York
-$2.83M
2
EC
EcoR1 Capital
California
-$2.48M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.39M
4
Jennison Associates
Jennison Associates
New York
-$672K
5
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$546K
Name Holding Trade Value Shares
Change 		Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$34.8M +$2.03M +195,172 +8%
MAM
2
MPM Asset Management
Massachusetts
$29.8M – – –
BlackRock
3
BlackRock
New York
$20.2M +$14.8M +1,425,057 +3,177%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$17.2M -$2.39M -229,731 -16%
ACH
5
ArrowMark Colorado Holdings
Colorado
$6.92M +$2.48M +238,533 +90%
O
6
OrbiMed
New York
$6.65M -$2.83M -272,565 -36%
Vanguard Group
7
Vanguard Group
Pennsylvania
$5.62M +$203K +19,522 +5%
Millennium Management
8
Millennium Management
New York
$4.08M +$2.05M +197,415 +197%
HIM
9
Hillhouse Investment Management
Cayman Islands
$3.37M +$2.55M +245,449 New
CAM
10
Cormorant Asset Management
Massachusetts
$3.3M – – –
BC
11
Boxer Capital
California
$3.21M – – –
AG
12
Artal Group
Luxembourg
$2.74M +$2.08M +200,000 New
Alyeska Investment Group
13
Alyeska Investment Group
Illinois
$2.37M -$546K -52,614 -23%
SFM
14
Sphera Funds Management
Israel
$2.28M – – –
Morgan Stanley
15
Morgan Stanley
New York
$1.65M +$843K +81,159 +209%
USAA
16
United Services Automobile Association
Texas
$1.42M -$43K -4,140 -4%
Point72 Asset Management
17
Point72 Asset Management
Connecticut
$1.36M +$1.03M +99,000 New
Geode Capital Management
18
Geode Capital Management
Massachusetts
$1.36M +$97.7K +9,410 +11%
TAM
19
Tiverton Asset Management
Delaware
$1.14M – – –
Northern Trust
20
Northern Trust
Illinois
$917K +$70.2K +6,758 +11%
State Street
21
State Street
Massachusetts
$841K +$23.9K +2,300 +4%
ACM
22
Asymmetry Capital Management
California
$824K +$624K +60,087 New
BCM
23
Bridgeway Capital Management
Texas
$693K +$524K +50,500 New
GPCM
24
Granite Point Capital Management
Massachusetts
$686K +$519K +50,000 New
DM
25
Deerfield Management
New York
$523K +$396K +38,130 New
1
2 3

SNDX Hedge Fund Activity: Q1 2017 in Review

63 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q1 2017, worth a combined $160M — up 100% from $79.8M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new SNDX positions and 3 closed out — a net gain of 12 holders — while 19 added to existing stakes and 11 trimmed.

The largest buyer was BlackRock, adding an estimated $14.8M. The largest seller was OrbiMed, cutting an estimated $2.83M.

  • 63 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q1 2017, up from 57 in Q4 2016.
  • Funds reported $160M of Syndax Pharmaceuticals stock for Q1 2017, up 100% quarter-over-quarter.
  • 15 funds opened new Syndax Pharmaceuticals positions in Q1 2017 and 3 closed out, a net change of +12 holders.
  • The largest Syndax Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $14.8M added.
  • The largest Syndax Pharmaceuticals seller in Q1 2017 was OrbiMed, an estimated $2.83M sold.

Based on aggregated 13F filings for Q1 2017.